← Browse by Condition

Medical Condition

parkinson s disease

Total Trials

21

Recruiting Now

21

Trial Phases

Phase 1, Phase 2, Phase 3

ClinicalMetric tracks all active clinical trials for parkinson s disease sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — parkinson s disease Clinical Trials

How many clinical trials are currently recruiting for parkinson s disease?

ClinicalMetric currently tracks 21 actively recruiting clinical trials for parkinson s disease, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 21. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for parkinson s disease?

parkinson s disease research spans Phase 1 (3 trials), Phase 2 (3 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a parkinson s disease clinical trial?

Eligibility criteria for parkinson s disease trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

3

Phase 2

3

Phase 3

1

Top Sponsors

AbbVie 2 trials

University of Cambridge 1 trial

Rumesa Butt 1 trial

Beijing Tiantan Hospital 1 trial

Innopeutics Corporation 1 trial

Recruiting Clinical Trials

The Role of METhanogens in the PROgression Of Parkinson's Disease and Related Neurological Conditions

University of Cambridge

Rhythmic Auditory Stimulaton Using Personalized Music Therapy in Parkinson's Disease

Study on Artificial Intelligence-Based Facial and Speech-Related Patterns in Parkinson's Disease and Their Digital Biomarkers

Beijing Tiantan Hospital

NCT07371338 Phase 1

Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients

Innopeutics Corporation

The Role of Concomitant Diseases in Postoperative Complications Risk Stratification.

Russian Federation of Anesthes...

A Study to Assess Change in Disease Symptoms in Adult Participants With Advanced Parkinson Disease Using Subcutaneous Foslevodopa/Foscarbidopa in Belgium

Physiological Brain Atlas Development

Vanderbilt University Medical ...

Combined Genome and RNA Sequencing for Genetic Diagnosis of Parkinsonism

University Hospital, Strasbour...

Natural History Protocol for Movement Disorders

National Institute of Neurolog...

NCT04396873 Phase 1

PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease

National Institute of Mental H...

Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease

United States, Canad...

NCT07312110 Phase 2

D-SPARK: A Clinical Trial of D-Serine for Modifying Parkinson's Disease Progression

Haukeland University Hospital

NCT05576818 Phase 3

Effect of Synbiotic as an Adjuvant Therapy in the Treatment of Parkinson's Disease

Tanta University

Combined STN and NBM Deep Brain Stimulation for Mild Cognitive Impairment in Parkinson's Disease

Helen M. Bronte-Stewart

NCT07733349 Phase 1, Phase 2

Phase I/II Clinical Trial of UX-DA003 Injection for the Treatment of Patients With Parkinson's Disease

Shanghai UniXell Biotechnology...

International Validation of Two Non-motor Scales in PD (NFS and SPARK)

France, Germany, Gre...

Insel Gruppe AG, University Ho...

Retinal Imaging in Neurodegenerative Disease

Duke University

Exercise as Treatment of Fatigue in Parkinson´s Disease

University of Aarhus

Kinematic and Neural Dynamics of Postural Instability in Parkinson's Disease

VA Office of Research and Deve...

NCT07592767 Phase 2

RESvEraTrol in Parkinson's Disease (RESET)

Georgetown University

The Swedish BioFINDER Sleep Study

Skane University Hospital

Related Conditions

mild cognitive impairment (4) alzheimer s disease (4) parkinson disease (2) rem sleep behavior disorder irbd (2) dementia (2) epilepsy (2) parkinson disease disorder (1) parkinson (1) rem behavior disorder (1) rem sleep behavior disorder (1) rem sleep behaviour disorder (1) constipation (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology